Amicus Therapeutics, Inc. (NASDAQ:FOLD)‘s stock had its “outperform” rating reiterated by stock analysts at Leerink Swann in a research note issued to investors on Saturday. They currently have a $17.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $18.00. Leerink Swann’s price objective would indicate a potential upside of 22.48% from the stock’s current price. Leerink Swann also issued estimates for Amicus Therapeutics’ Q3 2017 earnings at ($0.30) EPS, Q4 2017 earnings at ($0.30) EPS, FY2017 earnings at ($1.31) EPS, FY2018 earnings at ($1.06) EPS, FY2019 earnings at ($0.78) EPS and FY2020 earnings at ($0.55) EPS.

Several other analysts have also issued reports on the stock. Cowen and Company reiterated an “outperform” rating and set a $18.00 price target (up previously from $16.00) on shares of Amicus Therapeutics in a research report on Thursday. Chardan Capital reiterated a “buy” rating and set a $16.50 price target (down previously from $17.50) on shares of Amicus Therapeutics in a research report on Wednesday. BidaskClub upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 17th. J P Morgan Chase & Co reiterated an “overweight” rating and set a $15.00 price target (up previously from $13.00) on shares of Amicus Therapeutics in a research report on Wednesday, August 9th. Finally, Zacks Investment Research upgraded shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 19th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Amicus Therapeutics presently has an average rating of “Buy” and a consensus target price of $15.08.

Amicus Therapeutics (FOLD) opened at 13.88 on Friday. The company has a 50-day moving average of $13.20 and a 200 day moving average of $9.77. The company’s market cap is $2.28 billion. Amicus Therapeutics has a 52-week low of $4.41 and a 52-week high of $14.36.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.03. The business had revenue of $7.16 million for the quarter, compared to analyst estimates of $6.96 million. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. During the same quarter last year, the business posted ($0.40) EPS. Equities research analysts predict that Amicus Therapeutics will post ($1.37) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/09/16/amicus-therapeutics-inc-fold-stock-rating-reaffirmed-by-leerink-swann.html.

In related news, insider Jay Barth sold 30,000 shares of the stock in a transaction that occurred on Monday, June 19th. The shares were sold at an average price of $10.00, for a total value of $300,000.00. Following the completion of the transaction, the insider now owns 64,184 shares of the company’s stock, valued at approximately $641,840. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Life Sciences Maste Perceptive acquired 1,500,000 shares of the company’s stock in a transaction that occurred on Thursday, July 13th. The stock was bought at an average cost of $12.25 per share, with a total value of $18,375,000.00. The disclosure for this purchase can be found here. 3.40% of the stock is owned by corporate insiders.

A number of large investors have recently modified their holdings of the stock. FMR LLC lifted its stake in Amicus Therapeutics by 3.4% in the 2nd quarter. FMR LLC now owns 21,437,508 shares of the biopharmaceutical company’s stock valued at $215,876,000 after purchasing an additional 705,153 shares during the last quarter. Redmile Group LLC lifted its stake in Amicus Therapeutics by 5.9% in the 2nd quarter. Redmile Group LLC now owns 12,043,932 shares of the biopharmaceutical company’s stock valued at $121,282,000 after purchasing an additional 668,080 shares during the last quarter. Vanguard Group Inc. lifted its stake in Amicus Therapeutics by 5.0% in the 2nd quarter. Vanguard Group Inc. now owns 9,118,246 shares of the biopharmaceutical company’s stock valued at $91,821,000 after purchasing an additional 430,486 shares during the last quarter. Palo Alto Investors LLC lifted its stake in Amicus Therapeutics by 0.7% in the 2nd quarter. Palo Alto Investors LLC now owns 7,940,788 shares of the biopharmaceutical company’s stock valued at $79,964,000 after purchasing an additional 57,800 shares during the last quarter. Finally, Janus Capital Management LLC lifted its stake in Amicus Therapeutics by 3.6% in the 1st quarter. Janus Capital Management LLC now owns 7,136,697 shares of the biopharmaceutical company’s stock valued at $50,883,000 after purchasing an additional 244,906 shares during the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.